Ranibizumab can be used for long-term CRVO

Article

Visual acuity and central retinal thickness in patients with central retinal vein occlusion (CRVO) have been improved with intravitreal ranibizumab treatment, according to a study published in Retina.

Visual acuity and central retinal thickness in patients with central retinal vein occlusion (CRVO) have been improved with intravitreal ranibizumab treatment, according to a study published in Retina.

A team led by Dr Louis K. Chang, Edward S. Harkness Eye Institute, New York, USA, conducted a prospective interventional case study on 35 eyes of 35 patients with CRVO. The baseline mean visual acuity of the patients was 44.2 Early Treatment Diabetic Retinopathy Study letters, with a mean central macular thickness of 638 μm. Each patient was administered 0.5 mg of intravitreal ranibizumab at baseline and twice monthly thereafter. Patients who experienced leakage during fluorescein angiography, intraretinal haemorrhage, or macular oedema by optical coherence tomography, received additional ranibizumab.

The mean visual acuity of 32 of the 35 eyes improved by 16.5 letters and macular thickness was reduced to 164 μm after 12 months. At 24 months, 24 eyes demonstrated an improved visual acuity of 17.8 letters and macular thickness was reduced to 263 μm.

The results show that intravitreal ranibizumab significantly improves visual acuity and central retinal thickness in patients with CRVO. There were no occurrences of endophthalmitis, retinal detachment, or neovascularization. The treatment can last for up to 2 years, with a minimal number of side effects reported.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.